Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (August 2021)
13 slides from Medical Developments International's investor presentation, Aug 25, 2021
Slide 1: MVP Investor Presentation 2020/21 Results
MVP Investor Presentation 2020/21 Results Gordon Naylor, Chair Brent MacGregor, CEO 25 August 2021
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other
Slide 3: A transitional year for MVP … with COVID
A transitional year for MVP … with COVID Reclaimed marketing authorisations across Europe, in FY21 STATUTORY FINANCIALS $M Australia and began the process in Canada Gross Revenue 25.7 COVID was a serious headwind; but we are seeing recovery signs Gross Margin $ 19.1 CEO, Chair and Board changes Net
Slide 4: Gross Revenue Bridge: Europe Penthrox growth despite COVID
Gross Revenue Bridge Europe Penthrox growth despite COVID Overall gross revenue grew 9% over prior year… … with much of this growth from contract income Respiratory sales are lower – COVID-19 impact with late surge in FY20 buying, a milder cold and flu season and reduced community movement Lower Pen
Slide 5: EBIT Bridge: Reflects the unique features of the year
EBIT Bridge Reflects the unique features of the year COVID impact on our AU Penthrox and respiratory business Suppressed Penthrox sales in Q2 due to distributor inventory sell-through Modest growth of our Europe Penthrox Result is an underlying EBIT of ($4.4m) $9.0m of Impairments $9.5m of Penthrox
Slide 6: Australian business is recovering from COVID
Australian business is recovering from COVID Lockdowns are an ongoing challenge Penthrox Mundipharma Australia sell-through of inventory meant minimal sales for MVP in Q2 Once the sell-in period was over, and MVP in full control, we witnessed a rapid recovery of our business through the end of FY21
Slide 7: Penthrox sales showing growth again in Europe, driven by the UK & France
Penthrox sales showing growth again in Europe, driven by the UK & France In-market unit sales (3-month moving average) 14,000 12,000 Improving COVID environment 10,000 Increased access to hospitals 8,000 ~14,000 units sold in July, highest ever 6,000 Launch of Penthrox across Nordic region 4,000 Dis
Slide 8: The UK market is approaching a new threshold
The UK market is approaching a new threshold In-market unit sales (3-month moving average) 8000 Increased growth since May 2020 7000 June saw the highest ever month for UK 6000 hospital sales 5000 UK passing 6000 unit per month 4000 Birmingham Hospital study being 3000 marketed as tool to engage key
Slide 9: The current trend in France is encouraging
The current trend in France is encouraging No promotion + Mundi Promotion MVP units COVID 4,500 4,000 Highest sales since July 2019 3,500 Currently 1 Key Account Manager (KAM) 3,000 since March; 8 more to join in September 2,500 Principal investigator of seminal French 2,000 study to train our KAMs
Slide 10: Advancing our plans for longer-term growth
Advancing our plans for longer-term growth Penthrox – US Flow technology Following guidance from the FDA in April, we have worked Lidocaine has successfully advanced to with an advisory group to revise our clinical trial protocol ‘Stage 4’ commercial scale production capability We intend to submit r
Slide 11: We are building a global company
We are building a global company FY21 progress FY22 enhancements Commercial Operations overhaul in Australia, Further changes in AU; augmentation of Europe and in Europe team, based on Germany and Italy outcomes Medical Affairs focus to support commercial Further expansion of Medical Affairs resourc
Slide 12: MVP is preparing for growth
MVP is preparing for growth The market potential for Penthrox remains strong The first transformational changes are done … more changes will roll out this year Early signs in France are encouraging … and 8 new KAMs are beginning in September Both of our partners in Europe want to expand their territ
Slide 13: Medical Developments International
Medical Developments International
Medical Developments International — Investor Presentation (August 2021) on 6ix